NATIONAL INCUBATOR SHIFTS INTO GEAR, ANNOUNCING VACCINE AND INFECTIOUS DISEASE INNOVATION COHORT Six Australian infectious disease innovations receive $10.48 million to accelerate commercialisation potential
With
Jenny Herz,
Co-Founder and Executive Director
Biointelect
Danielle Shand,
General Manager
Biointelect Venturer
SEGMENT
Filmed in Sydney | September 2026
Biointelect Venturer is Australia’s national incubator for infectious disease innovation, helping promising Australian scientific innovators accelerate their path from discovery to impact. Funded by the Australian Government’s Medical Research Future Fund (MRFF) through the 2024 BioMedTech Incubator grant opportunity, Biointelect Venturer combines catalytic non-dilutive funding with commercialisation expertise, strategic guidance, networks and tailored support to progress early-stage innovations towards commercial and investment readiness. Managed and operated by Biointelect, the incubator builds on Biointelect’s deep expertise and success in supporting early-stage biotech and medtech commercialisation.
Biointelect Venturer has announced six Australian infectious disease innovations will share $10.48 million in the incubator’s first funding round giving the successful research teams the ability to advance their early-stage breakthroughs to commercial and investment readiness.
– AdaptiVax Pty Ltd
– Ebivanta Therapeutics Pty Ltd
– ENA Respiratory Pty Ltd
– Proboxis Biotechnology Pty Ltd
– Saccharide Therapeutics Pty Ltd
– SAMMvax Pty Ltd
The recipients address significant local and global unmet health needs in infectious disease and include three vaccine offerings, a unique nasal antiviral technology and two vaccine platform technologies.
The projects will now enter the Biointelect Venturer incubation program for up to two years and receive non-dilutive funding, tailored commercialisation support, expert mentoring and access to national and international networks to help progress their technologies to secure commercial interest and funding.
Biointelect Venturer was established through a $32.9 million Medical Research Future Fund (MRFF) grant from the Australian Government’s MRFF Medical Research Commercialisation initiative. It will support two national cohort intakes, this being the first, and a dedicated top-up round for high-potential projects as part of the program.
Biointelect Venturer is helping to build local capability in translational research and commercialisation and supporting the creation and growth of Australian biotech companies developing health technologies across the infectious disease sector. Ultimately the ambition is to strengthen Australia’s position as a global infectious disease innovation hub.
Source: Adapted from Biointelect media release (August 2026)
-
Occupational therapy creates profound impacts on client and patient lives
Margeaux Bartholomew-Carle is an Adelaide based registered Occupational Therapist and the Founder and CEO of Ardant.
Throughout her career, Margeaux has worked in various settings, including aged care, disability, assistive technology, prescription, and mental health. This diverse experience has deepened her understanding of the different needs among client groups.
-
Paediatric mental help for children of defence personnel, veterans and first responders
Dr Marg Rogers is a Senior Lecturer in Early Childhood Education at University of New England (UNE) in Armidale, New South Wales. She is a prominent figure in early childhood education New South Wales, and is also a Post Doctoral Fellow at the Manna Institute, a mental health research organisation within the regional university network across Australia, that is building place based research capacity to improve the mental health of regional, rural and remote Australia.
-
Changes in MBS bulk billing incentives address GP capacity in women’s health
Dr. Sneha Wadhwani, a General Practitioner in Bondi, and Conjoint Lecturer at UNSW School of Medicine, is actively involved in enhancing women’s health services across Australia. As the Co-founder and Clinical Director of Evoca Women’s Health, she highlights the significant improvements in funding for women’s health, particularly with the new MBS bulk billing incentives, in new codes, that commenced on November 1, 2025.
